

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

INSIDE INFORMATION PROPOSED SHARE REPURCHASE

This announcement is made by Genscript Biotech Corporation (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that subject to market conditions and discretion of the Board, the Company proposes to commence an on-market share repurchase programme of the Company’s ordinary shares of US\$0.001 each (the “**Share(s)**”) for up to a maximum consideration of HK\$700,000,000 after the expiry of the black-out period prior to the announcement of the interim results of the Company (the “**Proposed Repurchase**”).

Under the general mandate to repurchase (the “**Repurchase Mandate**”) Shares of the Company granted by shareholders of the Company (the “**Shareholders**”) to the Board at the annual general meeting (the “**AGM**”) of the Company held on 1 June 2018, the Directors are authorised to repurchase a maximum of 10% of the total number of Shares in issue on the date of the AGM, being 174,286,711 Shares. The Proposed Repurchase will be conducted in compliance with all laws applicable to the Company, including but not limited to the Company’s memorandum of association and the articles of association, the Cayman Companies Law and the Listing Rules.

The effect of the Proposed Repurchase will result in a reduction of the Company's total outstanding Shares and in turn improve the net asset value per Share. The Proposed Repurchase demonstrates the Board's confidence in the Company in its long term business prospects and would ultimately benefit the Company and create value for Shareholders. The Proposed Repurchase will only be conducted under circumstances which the Board considers to be appropriate and in the interest of the Company and its Shareholders as a whole. Shareholders and potential investors should however note that the execution of the Proposed Repurchase is always subject to market conditions and discretion of the Board. There is no assurance that the Proposed Repurchase will be executed at all or if executed, the timing and number of Shares involved.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares of the Company.

By order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 6 August 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*